inflammation related

Ataquimast inhibits IL-5 secretion along with that of TNF-a, IL-4 and GM-CSF from human cells.

Benzyl cinnamate (Benzylcinnamoate) is a natural product isolated from various plant species,with anti-inflammatory activity.

beta-Escin is a natural mixture of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.

(9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one is a major mechanism of Sinomenine. Sinomenine is an alkaloid derived from the Chinese herb Sinomenium acutum (Thunb.) Rehd. et Wils. (9α,13α,14α)-4-Hydroxy-3,7-dimethoxy-7,8-didehydromorphinan-6-one exhibits anti-inflammation effects.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Chlorthenoxazine (Chlorethylbenzmethoxazone) has anti-inflammatory activity.

[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]acetic acid (2-[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]ACETIC ACID) is an anti-inflammatory thiazole

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Sericoside, a triterpenoid compound, is obtained from Terminalia and exhibits potent anti-inflammatory properties. Additionally, sericoside displays robust lipolytic activity, thereby aiding in the reduction of skin wrinkles and improvement of skin texture.

ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.

Adenosine N1-oxide (1-Oxoadenosine), which is found in royal jelly, inhibited the secretion of inflammatory mediators by activated macrophages and reduced lethality in lipopolysaccharide (LPS)-induced endotoxin shock.

TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).

Ac-YVAD-CMK (Ac-Tyr-Val-Ala-Asp-CMK) is a selective and irreversible inhibitor of Caspase-1 and inhibits pyroptosis, IL-1β and IL-18. Ac-YVAD-CMK shows neuroprotective and anti-inflammatory capacity.

8-Epideoxyloganic acid possesses bioactivities of analgesia, homeostasis and anti-inflammatory. It has the potential to serve as anti-inflammatory agents during oxidative stress, the inhibition of ROS production, possibly through modulation of NOX activit

Anti-inflammatory agent 35 is a potent anti-inflammatory agent.

Anti-inflammatory agent 36 is an anti-inflammatory agent that exhibited dose-dependent inhibition of LPS-induced release of TNF-a and IL-6 in active RAW 264.7 mouse macrophages (IC50 = 3.69 μM and 3.68 μM, respectively).

GI254023X is a MMP9 and ADAM10 inhibitor with IC50 values ​​of 2.5 and 5.3 nM, respectively. GI254023X can also significantly inhibit the proliferation of Jurkat cells and induce apoptosis.

Galiximab (IDEC 114) is a primate-type anti-CD80 immunoglobulin G1 (IgG1)-like monoclonal antibody with antitumor activity that induces in vivo growth inhibition and prolongs survival of B-NHL tumor xenografts. Galiximab has been used in the study of hematologic malignancies.

Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b/c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).

Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antitumor effects to prevent human endothelial dysfunction induced by hypercholesterolemia and hyperglycemia.

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.

Cudarolimab (IBI-101) is a fully human anti-OX40 antibody with potential immune checkpoint inhibitory and anti-tumor activity for the study of cancer.

Revdofilimab (ABBV-368) is a human IgG monoclonal antibody targeting Tumor Necrosis Factor Receptor superfamily member 4 (OX 40) with potential anticancer activity for the study of metastatic solid tumors and non-small cell lung cancer.